. Author manuscript; available in PMC: 2016 Dec 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):e37–e42. doi: 10.1097/QAI.0000000000000976

Table 1. Characteristics of patients eligible for cryptococcal antigen (CrAg) screening, Western Cape, South Africa, September 1, 2012-August 31, 2013.

	CrAg screened (n=1151)	Not screened (n=3225)	P value
Female, n (%)	555 (48.2)	1649 (51.3)	0.02
Median age, years (IQR)	35.2 (29.6-41.4)	34.3 (29.3-40.8)	0.05
Incidence of disseminated cryptococcal disease, n (%)	9 (0.8)	49 (1.5)	0.07
Median time to CM, days (IQR)	103 (69-119)	155 (70-262)	0.48
ART started, n (%)	853 (74.1)	1556 (48.3)	<0.001
Median time to ART among those who started ART, days (IQR)	24(16-36)	33 (18-62)	<0.001

CrAg: cryptococcal antigen; CM: cryptococcal meningitis; ART: antiretroviral treatment